<DOC>
	<DOCNO>NCT00477971</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan dexamethasone , work different way stop growth plasma cell , either kill cell stop divide . Having autologous stem cell transplant replace blood-forming cell destroy chemotherapy , allow high dos chemotherapy give plasma cell kill . By reduce number plasma cell , disease may progress slowly . It yet know whether combination chemotherapy effective chemotherapy follow autologous stem cell transplant treat primary systemic amyloidosis . PURPOSE : This randomized phase III trial study side effect well give low-dose melphalan together dexamethasone work compare high-dose melphalan follow autologous stem cell transplant treat patient primary systemic amyloidosis .</brief_summary>
	<brief_title>Low-Dose Melphalan Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare hematologic response rate patient primary systemic amyloidosis treat conventional chemotherapy comprise low-dose melphalan dexamethasone vs high-dose melphalan follow autologous stem cell transplantation . - Compare toxicity regimens patient . Secondary - Compare overall progression-free survival patient treat regimen . - Compare regression organ involvement patient treat regimen . - Compare duration response patient treat regimen . - Correlate clonal burden time vitro amyloid formation clinical outcome patient treat regimen . - Compare quality life patient treat regimen . - Compare information-seeking behavior patient treat regimen . OUTLINE : This comprehensive cohort study comprise randomize option nonrandomized option . Patients consent randomization stratify risk group ( high vs low ) ECOG performance status ( 0-1 v 2 ) . They randomize 1 2 treatment arm . Patients consent randomization choose treatment arm . - Arm I : Patients receive low-dose melphalan IV 15-30 minute day 1 orally daily day 1-7 oral dexamethasone day 1-4 22-25 . Treatment repeat every 6 week 10 course absence disease progression unacceptable toxicity . - Arm II : Patients receive filgrastim ( G-CSF ) day -7 -3 undergo autologous hematopoietic stem cell ( HSC ) collection . Patients receive high-dose melphalan IV 1 hour day -2 -1 undergo autologous HSC transplantation day 0 . Blood bone marrow sample collect baseline . Samples examine PCR , cDNA , nucleotide sequence analysis determine VH VL gene family carrier status . Urine collect baseline analyze light-chain protein level exclusion chromatography . Quality life assess baseline , month 3 , 9 , 12 , completion study treatment , every 6 month 5 year . After completion study treatment , patient follow every 6 month 10 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary systemic amyloidosis Amyloid lightchain ( AL ) disease Monoclonal protein immunoelectrophoresis immunofixation serum urine OR abnormal free lightchain ratio The following amyloid syndromes* allow : Amyloid hepatomegaly Cardiomyopathy Proteinuria Peripheral autonomic neuropathy Soft tissue involvement include tongue , submandibular tissue , vascular claudication Diffuse interstitial pulmonary AL disease allow pulmonary function adequate allow safe transplantation NOTE : *Presence amyloid deposit plasmacytoma bone marrow vessel asymptomatic patient constitute amyloid syndrome No secondary familial amyloidosis No multiple myeloma lytic destructive bone lesion myeloma cast nephropathy No multiple myeloma &gt; 30 % plasma cell bone marrow No amyloidosis manifest carpal tunnel syndrome purpura PATIENT CHARACTERISTICS : ECOG performance status 02 Platelet count ≥ 100,000/mm³ Bilirubin ≤ 2.0 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 6 time ULN Creatinine ≤ 3.0 mg/dL No NYHA class IV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No HIV positivity PRIOR CONCURRENT THERAPY : Prior alkylating agent , immunosuppressive drug , steroid allow provide give &lt; 1 month Therapeutic steroid dose ≤ 15 mg per day ( equivalent ) allow discretion physician No concurrent participation another clinical trial involve pharmacologic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>primary systemic amyloidosis</keyword>
</DOC>